Desensitization describes a change in response; it does not automatically supply instructions for preventing that change. Hexarelin discussions often turn a small study into a confident rule about when everyone must stop and restart.
The paper “Does desensitization to hexarelin occur?” followed 12 healthy older adults during repeated exposure. The GH response attenuated partially, and a later assessment showed reversibility under the study conditions. The result concerns a measured hormonal response in that cohort, not a validated cycle for the general public.
Three claims that should remain separate
First, a response may diminish over repeated exposure. Second, that response may change again after exposure ends. Third, a particular schedule may preserve a meaningful health benefit safely. Evidence for the first two does not establish the third.
The study did not show that a borrowed schedule optimizes strength, fat loss, sleep or long-term health. Nor does a return of the laboratory response establish that all biological effects or risks have returned to a prior state.
This is why words such as “fully reset” can be misleading outside the precise measurement being discussed. They sound comprehensive even when the study evaluated only a limited response.
When reviewing a tolerance claim, identify the population, outcome and observation period. Ask whether the proposed consumer rule was actually tested or was invented by extending the authors' finding beyond its scope.
If someone is experiencing a change while using a hormone-related product, that change needs appropriate medical assessment. Escalating exposure to chase an earlier effect introduces another risk without resolving what the change means.
The responsible interpretation is that partial, reversible attenuation has been observed in a small research setting. It is not a personalized forecast and not a reason to publish a cycling protocol. This article intentionally leaves the experiment as evidence rather than turning it into instructions.